Who are Avirmax's investors?

Avirmax's investors include 3E Bioventures Capital, BioVentures.

How much funding has Avirmax raised?

Avirmax has disclosed $3M raised across 1 round.

Where is Avirmax headquartered?

Avirmax is headquartered in Hayward, US.

Avirmax

Hayward, US · Founded 2019 · Delaware corporation · 2 known investors

Find your way into Avirmax

73 people in our graph share verified history with the Avirmax team — schools, employers, funds. One of them is your warm intro.

Glenn Pierceunlockedknows Haifeng Chen · together at Avigen, Inc. (overlapped)

×5knows the team · via Sun Yat-sen University

×3knows the team · via Universität des Saarlandes

×2knows the team · via Sichuan University

knows the team · via Cell Genesys

Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases. Through its Avirmax CMC (ACI) division, it also provides bioprocess development and manufacturing services for AAV-based gene therapies to external customers.

Biotech Deep Tech Medical Devices

Founders & leadership

Haifeng Chen inDirector and Treasurer of the IssuerHaifeng Chen is Director and Treasurer of Avirmax with over 10 years of experience in adeno-associated virus vector design, production, and characterization, as well as expertise in gene expression cassette construction and large-scale insect cell culture using Wave bioreactor systems.

Shengjiang LiuNamed on SEC filing

Board

Yu FangDirector of the IssuerGeneral Partner at BioVentures

Qianye Karen LiuDirector of the IssuerGeneral Partner at BioVentures

Nancy ChangDirector of the Issuer

Investors · 2

3E Bioventures CapitalPalo Alto

BioVenturesreportedBelmont

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 1 round · 2019

▶$3MraisedNov 2019 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Yu FangDirector
Qianye Karen LiuDirector
Haifeng ChenExecutive Officer, Director
Shengjiang LiuExecutive Officer, Director
Nancy ChangDirector

Offering amount: $10M
Amount sold: $3M
First sale: Nov 2019
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

1Mg4 shared keywordsThis is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth. The page provides usage instructions, benefits, side effects, and purchase/return details rather than describing a company.

Companies competing with Avirmax for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Avirmax Biopharma Initiates IND-enabling Studies of ABI-201; a Breakthrough Gene Therapy for Dry Age-related Macular Degenerationprnewswire.com · Feb 2025

Frequently asked questions

What does Avirmax do?: Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases. Through its Avirmax CMC (ACI) division, it also provides bioprocess development and manufacturing services for AAV-based gene therapies to external customers.
Who are Avirmax's investors?: Avirmax's investors include 3E Bioventures Capital, BioVentures.
How much funding has Avirmax raised?: Avirmax has disclosed $3M raised across 1 round.
Where is Avirmax headquartered?: Avirmax is headquartered in Hayward, US.